Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III randomized, double blind trial of LdT (telbivudine) versus lamivudine in Chinese adults with compensated chronic hepatitis B

Next Previous
X
Search
Trial Profile

A phase III randomized, double blind trial of LdT (telbivudine) versus lamivudine in Chinese adults with compensated chronic hepatitis B

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 19 Feb 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Telbivudine (Primary) ; Lamivudine
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Sponsors Idenix Pharmaceuticals

    • Most Recent Events

    • 01 Feb 2018 Results of retrospective analysis assessing effect of HBV subgenotype on treatment response using patient data from NCT00962533, NCT00057265 and NCT00131742 trials published in the Hepatology Research
    • 01 May 2007 Status changed from in progress to completed
    • 17 Nov 2005 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top